RecruitingNCT00869817
Dominantly Inherited Alzheimer Network (DIAN)
Sponsor
Washington University School of Medicine
Enrollment
700 participants
Start Date
Jan 1, 2009
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This international study (called DIAN) is following the adult children of people with a rare inherited form of Alzheimer's disease, to understand how the disease develops before symptoms appear and to test potential treatments.
**You may be eligible if...**
- You are 18 or older and have a parent with a confirmed inherited (dominantly inherited) form of early-onset Alzheimer's disease
- Your memory and thinking are normal, or you have only mild to moderate cognitive changes (CDR score 0–1.0)
- You are more than 15 years away from the age when your parent first showed symptoms (primary focus)
- You have two people (not full siblings) who can provide information about you to the study
- You speak a language approved by the study center at about a 6th grade level or above
**You may NOT be eligible if...**
- You are under 18
- You have a medical or psychiatric illness that would prevent completing study visits
- You require nursing home level care
- You have no one available to serve as a study informant
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(26)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT00869817
Related Trials
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
NCT071696301 location
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
NCT06976216106 locations
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)
NCT072349426 locations
Study on the Effect of 40 Hz Non-Invasive Light Therapy System
NCT052601771 location
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
NCT06976203123 locations